Unknown

Dataset Information

0

Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.


ABSTRACT: Chimeric antigen receptor (CAR) T cell therapies have demonstrated impressive initial response rates in hematologic malignancies. However, relapse rates are significant, and robust efficacies in other indications, such as solid tumors, will likely require novel therapeutic strategies and CAR designs. To that end, we sought to develop simple, highly selective targeting domains (D domains) that could be incorporated into complex, multifunctional therapeutics. Herein, we describe the identification and characterization of D domains specific for CD123, a therapeutic target for hematologic malignancies, including acute myelogenous leukemia (AML). CARs comprised of these D domains mediate potent T cell activation and cytolysis of CD123-expressing target cells and induce complete durable remission in two AML xenograft models. We describe a strategy of engineering less immunogenic D domains through the identification and removal of putative T cell epitopes and investigate the binding kinetics and affinity requirements of the resultant D domain CARs. Finally, we extended the utility of D domains by generating functional, bi-specific CARs comprised of a CD123-specific D domain and a CD19-specific scFv. The properties of D domains suggest that this class of targeting domain may facilitate the development of multi-functional CARs where conventional, scFv-based designs may be suboptimal.

SUBMITTER: Qin H 

PROVIDER: S-EPMC6612629 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.

Qin Haiying H   Edwards Justin P JP   Zaritskaya Liubov L   Gupta Ankit A   Mu C Jenny CJ   Fry Terry J TJ   Hilbert David M DM   LaFleur David W DW  

Molecular therapy : the journal of the American Society of Gene Therapy 20190417 7


Chimeric antigen receptor (CAR) T cell therapies have demonstrated impressive initial response rates in hematologic malignancies. However, relapse rates are significant, and robust efficacies in other indications, such as solid tumors, will likely require novel therapeutic strategies and CAR designs. To that end, we sought to develop simple, highly selective targeting domains (D domains) that could be incorporated into complex, multifunctional therapeutics. Herein, we describe the identification  ...[more]

Similar Datasets

| S-EPMC3814731 | biostudies-literature
| S-EPMC4624420 | biostudies-literature
| S-EPMC7393323 | biostudies-literature
| S-EPMC3393096 | biostudies-literature
| S-EPMC7461863 | biostudies-literature
| S-EPMC3881605 | biostudies-literature
| S-EPMC4993583 | biostudies-literature
| S-EPMC6292203 | biostudies-literature
| S-EPMC5444493 | biostudies-literature
| S-EPMC5542631 | biostudies-literature